This content is machine translated HER2-positive breast carcinoma New substances enable targeted therapy The HER2 receptor belongs to the family of four transmembrane receptor tyrosine kinases (EGFR/HER1, HER2, HER3, and HER4) that influence cell growth, differentiation, and survival. Overexpression of HER2 occurs in…
View Post 3 min This content is machine translated Female tumors From the “old-fashioned” CMF to the modern T-DM1 Over the past two decades, the prognosis of breast carcinoma has improved significantly. As a rule, 75% of patients are cured today. The introduction of modern chemotherapeutic agents, particularly taxanes,…
View Post 4 min This content is machine translated HER2-positive breast cancer and lymphoma New applications and antibodies The antibody-drug conjugate trastuzumab emtansine, T-DM1 (Kadcyla®), is composed of the antibody trastuzumab and the chemotherapeutic agent DM1 and is currently being investigated for the treatment of HER2-positive cancers. It…
